ARCHIVES

Auditor Raymond Weiss Finds “Incredible” Protocol Violations–26% Of Patients Were Ineligible For C225 Study

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

DCPC Begins Reassessment of Year 2000 Goals; Advisors Discuss A ‘More Dynamic Model’

May 22, 1992

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

November 7, 2003

Drug Development Gets Extra $500,000

November 18, 1977

FDA Continues Bureaucratic Delays Of Cancer INDs

January 30, 1976

Foreeman, Brinker, Jako Appointed To Cancer Panel

April 19, 1991

Three Cancer Centers Test Targeted Therapy For Resistant Acute Myelogenous Leukemia

July 26, 2002